Has Stephen Krieger, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,098,183 in general payments to Stephen Krieger, MD across 807 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Stephen Krieger, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Stephen Krieger, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Stephen Krieger, MD

Neurology · New York, NYNPI 1417023367

Payments from drug & device makers

$3,098,183in general payments, 2019–2025

Across 807 payments — averaging $3839.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi$1.1M
Bristol Myers Squibb$654K
Novartis$307K
Genentech USA, Inc.$256K
Biogen$214K
TG Therapeutics, Inc.$167K
plus $365K from 18 others

$156,590in research payments, 2019–2025

Across 16 payments — averaging $9786.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

EMD Serono Research & Development Institute, Inc.$119K
TG Therapeutics, Inc.$26K
EMD Serono, Inc.$9K
F. Hoffmann-la Roche AG$3K

What the payments were for

Consulting fees$376,34333%
Speaking & faculty fees$626,63855%
Travel & lodging$111,71810%
Food & beverage$20,9072%
Education$2950%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi	102	$1,134,964
Bristol Myers Squibb	13	$654,272
Novartis	88	$306,921
Genentech USA, Inc.	129	$256,261
Biogen	154	$214,327
TG Therapeutics, Inc.	107	$166,735
EMD Serono, Inc.	133	$153,459
Genentech, Inc.	36	$96,861
Novartis Pharma AG	7	$20,960
Jazz Pharmaceuticals Inc.	3	$18,117
F. Hoffmann-la Roche AG	9	$15,876
Cycle Pharmaceuticals Inc	6	$14,561
EMD Serono Research & Development Institute, Inc.	1	$12,677
Merck Kgaa	5	$12,292
Sanofi US Services Inc.	3	$11,896
Merck Serono S.p.a.	1	$2,120
Mallinckrodt Enterprises LLC	1	$2,100
Janssen Scientific Affairs, LLC	1	$1,320
PTC Therapeutics, Inc.	2	$1,153
Banner Life Sciences, LLC	1	$900
Acorda Therapeutics, Inc	2	$259
E.r. Squibb & Sons, L.L.C.	1	$85
Teva Pharmaceuticals USA, Inc.	1	$35
AstraZeneca	1	$31

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

BRIUMVI$164,234
OCREVUS$159,408
Nityr$13,125
KESIMPTA$12,531
ARZERRA$9,317
Vumerity$8,557
TYSABRI$8,457
DISEASE STATE$7,812
Mavenclad$6,267
TECFIDERA$5,504
AVONEX$5,368
PLEGRIDY$5,368
Evobrutinib$5,300
Non-Covered Product$5,148
Enspryng$3,330
ACTHAR$2,100
Tascenso ODT$1,400
Bafiertam$900
MAYZENT$250
ZEPOSIA$227

How this compares

$3,098,183 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York →

Medicare billing

Part B allowed, 2024

$23,501

Medicare patients

Services billed

253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Dalfampridine ErDalfampridine	16	$5,539
Baclofen	24	$683
Gabapentin	18	$260
Pregabalin	11	$245

Paid to pharmacies, not to this prescriber.

Other neurology in New York

Christian GrommesNew York$9.9M
Ilya KisterNew York$9.5M
E DorseyNew York$8.5M
Lauren SchaffNew York$8.2M
Martin SadowskiNew York$5.4M
Lawrence HonigNew York$4.9M
Sheng-Han KuoNew York$3.2M
Thomas KaleyNew York$2.9M
Aaron MillerNew York$2.8M
Andrew LassmanNew York$2.6M

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →